Agilent Names Alacris Theranostics as Certified Provider of Target Enrichment Services
News Jan 17, 2015
Agilent Technologies Inc. has announced that it has named Alacris Theranostics, a Berlin-based company active in the area of next-generation sequencing (NGS)-driven personalized medicine, as an Agilent Certified Service Provider for target enrichment.
Agilent certifies select laboratories that leverage the company's market-leading technologies to provide analysis services of the highest quality. Hands-on training from application scientists on Agilent's proven workflow solutions ensures that customers receive consistent data quality, reproducibility and reliability.
"We are honored to have Alacris Theranostics as part of the Agilent CSP program," said Alessandro Borsatti, senior director of marketing for Agilent's Diagnostics and Genomics Group. "Alacris is known for providing innovative approaches to cancer research and has used Agilent's NGS target enrichment solutions for several years. We look forward to supporting them as they expand their work."
"Becoming an Agilent CSP for targeted enrichment services confirms the high standards adopted by Alacris," said Dr. Bodo M.H. Lange, chief executive at Alacris. "Certification will help to expand our growing reputation and assure our customers and collaborators in the sequencing and personalized medicine sector that we will deliver high-quality results."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.